Roche NimbleGen and Kapa Biosystems Team Up to Provide Optimized Next-Generation Sequencing (NGS) Target Enrichment Workflow

  Roche NimbleGen and Kapa Biosystems Team Up to Provide Optimized
  Next-Generation Sequencing (NGS) Target Enrichment Workflow Solution

Business Wire

MADISON, Wis. -- December 20, 2013

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Kapa Biosystems announced today a
partnership to provide an optimized NGS target enrichment workflow solution.
Kapa Biosystems will custom manufacture NGS library preparation products for
Roche NimbleGen to distribute to its customers.

Roche NimbleGen’s new offering combines KAPA Library Preparation Kits with
Roche NimbleGen sequence capture products for complete workflow coverage,
prior to sequencing. This validated protocol provides customers with the
ability to work with low DNA quantity or quality, including FFPE DNA for whole
exome or targeted sequencing. Compared to other workflows, this offering
significantly reduces GC bias and obtains better molecular complexity,
resulting in further improved enrichment performance.

“In addition to providing innovative technologies, Roche NimbleGen has always
been committed to maximizing customer convenience, and we make every effort to
achieve this goal,” said Rebecca Selzer, President, Roche NimbleGen, “now our
customers have a complete and streamlined workflow solution, from the
combination of two industry-leaders with a reputation of high performing

“Our partnership with Roche NimbleGen brings together complementary,
best-in-class products for target enrichment, enabling higher quality
sequencing across a broad range of sample types and DNA inputs. We are
committed to continuously providing customers with enhanced product
functionality that addresses the growing diversity of sequencing
applications,” said John Foskett, Co-Founder and Chief Technology Officer of
Kapa Biosystems.

In addition to the KAPA Library Preparation Kits, Roche NimbleGen will also
introduce other reagents in this offering to support the target enrichment
workflow. All new products in this offering are available for ordering.

Terms and financials of the partnership were not disclosed.

About Kapa Biosystems

Kapa Biosystems is a life science reagents supplier that employs proprietary,
directed evolution technologies to optimize enzymes for PCR, real-time PCR,
next generation sequencing and molecular diagnostic applications. Kapa
Biosystems offers a portfolio of best-in-class products containing novel
enzymes that confer significant performance advantages when compared to
traditional wild-type enzymes. The company is based in Wilmington,
Massachusetts with a research, development and manufacturing facility in Cape
Town, South Africa. For more information, please visit

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused
healthcare with combined strengths in pharmaceuticals and diagnostics. Roche
is the world’s largest biotech company, with truly differentiated medicines in
oncology, infectious diseases, inflammation, metabolism and neuroscience.
Roche is also the world leader in in vitro diagnostics and tissue-based cancer
diagnostics, and a frontrunner in diabetes management. Roche’s personalised
healthcare strategy aims at providing medicines and diagnostic tools that
enable tangible improvements in the health, quality of life and survival of
patients. In 2012 Roche had over 82,000 employees worldwide and invested over
8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss
francs. Genentech, in the United States, is a wholly owned member of the Roche
Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For
more information, please visit

NIMBLEGEN and SEQCAP are trademarks of Roche.

KAPA is a trademark of Kapa Biosystems.

All other product names and trademarks are the property of their respective


Roche Sequencing
Beth Button, +1-317-847-5172
Kapa Biosystems
Brian Komorous, +1-855-KAPABIO (527-2246)
Press spacebar to pause and continue. Press esc to stop.